Overview

CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects

Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending oral doses of CKD-504 compared to placebo in healthy Korean and Caucasian adult subjects
Phase:
Phase 1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Treatments:
Histone Deacetylase Inhibitors